Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19793239 | 0.89 | GRM4 (1.00) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19793210 | 0.87 | GRM4 (0.79) | GRM4CYP1A2 | |
| SCHEMBL19793204 | 0.87 | GRM4 (0.76) | GRM4CYP1A2 | |
| SCHEMBL19793202 | 0.86 | GRM4 (0.75) | GRM4CYP1A2 | |
| SCHEMBL19793028 | 0.85 | GRM4 (0.81) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19793249 | 0.85 | GRM4 (0.81) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19793081 | 0.85 | GRM4 (0.74) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19792950 | 0.85 | GRM4 (1.00) | GRM4CYP1A2 | |
| SCHEMBL19793047 | 0.84 | GRM4 (0.77) | GRM4CYP1A2CYP2C9 | |
| SCHEMBL19793155 | 0.84 | GRM4 (0.73) | GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRM1 | GRM4 2/4885CYP1A2 3387/4885CYP2C9 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.